SAN CARLOS, Calif.--(EON: Enhanced Online News)--Natus Medical Incorporated (NASDAQ: BABY) today announced financial results for the three months ended September 30, 2013.
“I am very pleased to report our third quarter results. We exceeded our revenue and earnings guidance and improved our non-GAAP gross profit margin to 61%”
For the third quarter ended September 30, 2013, the Company reported revenue of $85.4 million, up 5% from $81.0 million in the third quarter of the previous year. Net income was $6.3 million, or $0.20 per diluted share, compared with a net loss of $1.7 million, or $0.06 per share, in the third quarter of 2012.
For the nine months ended September 30, 2013, the Company reported revenue of $253.5 million, compared to $201.5 million in the comparable period of the previous year. Net income was $13.7 million, or $0.45 per diluted share, compared with a net loss of $1.1 million, or $0.04 per share, for the nine months ended September 30, 2012.
The Company reported non-GAAP earnings per share of $0.30 per diluted share for the third quarter 2013, up 88% from the $0.16 per diluted share reported for the third quarter of 2012, and $0.65 per diluted share for the nine months ended September 30, 2013, up 91% from the $0.34 per diluted share reported for the same period in the previous year.
The Company’s cash and cash equivalents increased $15.3 million to $44.2 million during the quarter and total debt was reduced by $2.5 million.
“I am very pleased to report our third quarter results. We exceeded our revenue and earnings guidance and improved our non-GAAP gross profit margin to 61%,” said Jim Hawkins, President and Chief Executive Officer of the Company. “This was driven by stronger than expected results from both our neurology and newborn care businesses. Both our domestic and international results exceeded our expectations and we saw noticeable improvements in the European market. We also ended the quarter with a higher order backlog.”
“Our third quarter non-GAAP operating margin of 15% is very satisfying and we now expect to reach our full-year 2013 non-GAAP operating profit margin goal of 12%. These results move us closer to our long-term non-GAAP operating profit margin goal of 13% to 17%,” Hawkins added. “We have made great progress in our operating results and cash generation while building market leading franchises in both Neurodiagnostics and Newborn Care.”
The Company increased revenue and earnings guidance for the fourth quarter and full year 2013.
For the fourth quarter 2013, the Company now expects revenue of $87 million to $90 million and non-GAAP earnings per share of $0.30 to $0.32. This compares to prior revenue guidance for the fourth quarter 2013 of $84 million to $88 million and non-GAAP earnings per share of $0.22 to $0.25.
For the full year 2013 the Company now expects revenue of $340 million to $343 million and non-GAAP earnings per share of $0.95 to $0.97. This compares to prior revenue guidance for the full year 2013 of $332 million to $338 million and non-GAAP earnings per share of $0.76 to $0.82.
Included in the Company’s 2012 third and fourth quarter revenues were one time shipments of proprietary product to CareFusion. Natus agreed to manufacture this product for CareFusion through a supply agreement that was part of the purchase of Nicolet. These one-time revenues totaled $3.4 million; $1.2 million in the third quarter and $2.2 million in the fourth quarter of 2012.
The Company's non-GAAP earnings guidance excludes amortization of acquisition related intangibles, acquisition related charges, restructuring charges, and their related tax effects.
The Company’s non-GAAP earnings guidance includes the impact of expensing employee share based compensation. All non-GAAP earnings per share amounts are on a diluted basis.
Use of Non-GAAP Financial Measures
The Company's non-GAAP results exclude amortization expense associated with certain acquisition-related intangibles, restructuring charges, and direct costs of acquisitions. A reconciliation between non-GAAP and GAAP financial measures is included on page 6 of this press release.
The Company believes that the presentation of results excluding these charges provides meaningful supplemental information to both management and investors that is indicative of the Company's core operating results. Therefore, the Company believes these non-GAAP financial measures facilitate comparison of operating results across reporting periods.
The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing the Company's performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated.
Natus has scheduled an investment-community conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) today, October 24, 2013. Individuals interested in listening to the conference call may do so by dialing 1-877-280-4953 for domestic callers, or 1-857-244-7310 for international callers, and entering reservation code 96300493. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-888-286-8010 for domestic callers, or 1-617-801-6888 for international callers, and entering reservation code 66408345.
The conference call also will be available real-time via the Internet at http://investor.natus.com, and a recording of the call will be available on the Company’s Web site for 90 days following the completion of the call.
About Natus Medical Incorporated
Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.
Additional information about Natus Medical can be found at www.natus.com.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include statements regarding the benefit of cost improvement initiatives, the goal of driving non-GAAP operating margins to long-term goals of 13%-17%, revenue and non-GAAP profitability in the fourth quarter and full year 2013, the impact of amortization expense associated with acquisition-related intangible assets and any expected restructuring charges. These statements relate to current estimates and assumptions of our management as of the date of this press release, and future events or Natus' future financial performance or results, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. Our future results could differ materially due to a number of factors, including the effects of competition, the demand for our products and services, the impact of adverse global economic conditions on our target markets, our ability to expand our sales in international markets, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, risks associated with bringing new products to market and integrating acquired businesses, and our ability to fulfill product orders on a timely basis. Natus disclaims any obligation to update information contained in any forward looking statement.
More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2012, and its quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.
|NATUS MEDICAL INCORPORATED AND SUBSIDIARIES|
|UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(in thousands, except per share amounts)|
|Quarter Ended||Year to Date|
|Cost of revenue||34,058||36,456||104,518||89,237|
|Marketing and selling||20,337||21,805||64,305||54,693|
|Research and development||7,536||8,513||24,337||21,844|
|General and administrative||14,323||18,811||40,160||39,206|
|Total operating expenses||42,195||49,129||128,802||115,743|
|Income from operations||9,138||(4,566||)||20,155||(3,521||)|
|Other income/(expense), net||(580||)||(218||)||(1,437||)||259|
|Income before tax||8,558||(4,784||)||18,718||(3,262||)|
|Provision for income tax expense||2,271||(3,037||)||4,969||(2,128||)|
|Earnings per share:|
|NATUS MEDICAL INCORPORATED AND SUBSIDIARIES|
|RECONCILIATION OF NON-GAAP ADJUSTMENTS (UNAUDITED)|
|(in thousands, except per share amounts)|
|Quarter Ended||Year to Date|
|GAAP based results:|
|Income before provision for income tax||$||8,558||$||(4,784||)||$||18,718||$||(3,262||)|
|Amortization of acquired intangibles:|
|Cost of revenue||796||703||2,361||1,763|
|Marketing and selling||686||564||2,021||1,493|
|Research and development||341||338||967||1,013|
|Restructuring charges (G&A)||1,938||7,671||2,020||8,927|
|Direct costs of acquisitions (G&A)||-||786||1,774||2,778|
|Accelerate ERP system depreciation (G&A)||-||-||-||902|
|Backlog FMV Adjustments (Marketing & Sales)||-||720||-||720|
|Inventory FMV adjustment (COGS)||-||571||-||626|
Non-GAAP income before provision for income tax
|Income tax expense, as adjusted||3,231||1,928||7,932||4,768|
|Non-GAAP net income||$||9,088||$||4,641||$||19,929||$||10,192|
|Non-GAAP earnings per share:|
Weighted-average shares used to compute
|Basic non-GAAP earnings per share||30,096||29,062||29,823||28,947|
|Diluted non-GAAP earnings per share||30,791||29,822||30,576||29,584|
|GAAP Gross profit||51,334||44,563||148,957||112,222|
|Amortization of intangibles||796||703||2,361||1,763|
|Backlog FMV adjustment||-||571||-||626|
|Non-GAAP Gross Profit||52,130||45,837||151,318||114,611|
|Non-GAAP Gross Margin||61.0||%||56.6||%||59.7||%||56.9||%|
|GAAP Operating profit||9,138||(4,566||)||20,155||(3,521||)|
|Amortization of intangibles||1,823||1,605||5,349||4,269|
|Restructuring and other charges||1,938||9,748||3,794||13,953|
|Non-GAAP Operating profit||12,899||6,787||29,298||14,701|
|Non-GAAP Operating margin||15.1||%||8.4||%||11.6||%||7.3||%|
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
|CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)|
|Cash and cash equivalents||$||44,192||$||28,910|
|Accounts receivable, net||84,803||87,557|
|Other Current Assets||14,235||14,605|
|Total current assets||182,607||169,978|
|Property and equipment, net||24,425||25,842|
|Goodwill and Intangible assets||199,699||200,544|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Total current liabilities||75,430||71,951|
|Long-term debt, net||37,500||40,381|
|Other long-term liabilities||14,125||13,120|
|Total stockholders’ equity||288,712||279,358|
|Total liabilities and stockholders’ equity||$||415,767||$||404,810|